Advertisement

Topics

The Biogen Idec Foundation Company Profile

11:12 EDT 26th September 2018 | BioPortfolio


News Articles [872 Associated News Articles listed on BioPortfolio]

Creating an urgency to change. Mikael Nilsson, Director of Marketing Excellence, Biogen Idec

Of the 20 to 60 thousand thoughts we have per day only about 2% are new. Most of our thoughts are old thoughts and that tells us something about the challenge to change. During the eyeforpharma confe...

Nomura wertet Biogen-Studie zu Alzheimer-Wirkstoff psoitiv

Das japanische Analysehaus Nomura hat die Einstufung für Biogen Idec nach positiven Daten zum Wirkstoff BAN2401 gegen Alzheimer auf "Buy" mit einem Kursziel von 420 US-Dollar belassen. Mit den Erg...

Pooled analysis results of adalimumab, etanercept and infliximab biosimilars

South Korean electronics giant Samsung and biotechnology company Biogen Idec (Biogen) joint venture Samsung Bioepis, along with Biogen, announced on 13 June 2018 results of a pooled analysis combining...

wikifolio whispers p.m. zu Baumot Group, Innogy, Biogen Idec ...

Aktuelle Kommentare aus dem wikifolio-Universum. Mit Links zu den jeweiligen Depots, damit man sieht, wie erfolgreich die Kommentatoren mit ihren Einschätzungen sind und wie sich die genannten Inpu.....

Biogen Inc.: Biogen Appoints Daniel Karp as EVP, Corporate Development

Seasoned executive brings strong track record of success leading licensing and M&A transactions CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Biogen (http://www.biogen.com/) (Nasdaq:BIIB) ann...

Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI (Adalimumab Biosimilar) in Europe

Biogen expects to launch IMRALDI in Europe on October 16, 2018 Biogen will be the first company to offer biosimilars of all three major anti-TNF therapies in Europe Biogen Inc. (Nasdaq: BIIB) and ...

Biogen, Neurimmune Announce Option Exercise For Aducanumab

NewsBiogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 i...

Biogen Foundation Selects Grantees to Receive $10 Million Investment for STEM Education

CAMBRIDGE, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- The Biogen Foundation today announced the six nonprofits that will share a previously-announced four-year, $10 million grant to drive the develop...

Drugs and Medications [454 Associated Drugs and Medications listed on BioPortfolio]

Esika [Ventura Corporation (San Juan, P.R)]

ēsika 3-in-1 Pro Make Up Foundation SPF 20

Sheer cover mineral foundation [Guthy-Renker LLC]

Sheer Cover Mineral Foundation SPF-15

Cle de peau beaute silky foundation i [SHISEIDO CO., LTD.]

CPB Silky Cream Foundation I

Cle de peau beaute foundation i [SHISEIDO CO., LTD.]

cle de peau BEAUTE Cream Foundation I

Shiseido perfect refining foundation [SHISEIDO AMERICA INC.]

SHISEIDO Perfect Refining Foundation

PubMed Articles [220 Associated PubMed Articles listed on BioPortfolio]

The Florence Nightingale Foundation: developing nursing's leaders.

Ursula Ward, Chief Executive, Florence Nightingale Foundation, chiefexec@florence-nightingale-foundation.org.uk , describes the role of the foundation and its plans for the future.

A Review on Clinical Pharmacokinetics, Pharmacodynamics, and pharmacogenomics of natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody.

Natalizumab (Tysabri®, Biogen-Idec Inc., NAT), a humanized anti-α4 integrin monoclonal antibody, binds in both α4β1 (Very Late Antigen 4, VLA-4) and α4β7 (lymphocytes Peyer's patch adhesion mole...

Comments on Feskanich et al.: Milk and other dairy foods and risk of hip fracture in men and women.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.

Association between gout and osteoporosis risk in the United Kingdom.

Clinical Trials [265 Associated Clinical Trials listed on BioPortfolio]

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled I...

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

The purpose of this study is to determine whether anti-CD80 monoclonal antibody (IDEC-114) is effective in the treatment of follicular B-cell non-Hodgkin's lymphoma. This drug has never b...

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® [Rituxan® as a single agent is ...

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change cert...

Pregnancy Exposure Registry for AVONEX

This is an observational, exposure-registration and follow-up study, which will be conducted in the United States (US). The AVONEX® Pregnancy Exposure Registry is designed to monitor pre...

Companies [1401 Associated Companies listed on BioPortfolio]

Biogen Idec Inc.

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Elan Corporation, plc

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufa...

Biogen Idec and Abbott

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in ...

Biogen Idec and Portola Pharmaceuticals

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in ...

Biogen Idec

Scientific excellence that achieves new standards of care drives the company's work. 17 products are currently in clinical development addressing a variety of key medical needs.With patients in more t...

More Information about "The Biogen Idec Foundation" on BioPortfolio

We have published hundreds of The Biogen Idec Foundation news stories on BioPortfolio along with dozens of The Biogen Idec Foundation Clinical Trials and PubMed Articles about The Biogen Idec Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Biogen Idec Foundation Companies in our database. You can also find out about relevant The Biogen Idec Foundation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record